The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive ...
The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...
EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic ...
“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.
Dana White has been ordered to testify in an ongoing antitrust lawsuit against the UFC.
Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...
Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...
County supervisors this week approved $3.5 million to remove the bunks, which state inspectors have repeatedly ordered the ...
High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...
Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
Over 1.5 million people globally experience gradual vision loss due to retinitis pigmentosa (RP). This condition comprises a group of inherited eye disorders characterized by the degeneration of cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback